Close Menu

NEW YORK – Although there are well-established treatments for many of the cancers that occur in children, there are cases where reliable treatments do not exist, particularly for pediatric cancers that recur.

Those difficult-to-treat cases are among those being tackled through KidsCanSeq, a Texas-based  genomics-centered pediatric oncology study. The effort was launched in 2018 with $2.8 million in funding from the second phase of the National Human Genome Research Institute's Clinical Sequencing Evidence-Generating Research Consortium, known as CSER2.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.